Skip to content
Home
About Us
Contributors
Publications
Aron 1 – Renal Cell Carcinoma
Aron 2 – Urothelial carcinoma
Aron 3 – Prostate Cancer
Aron – supplementaries
Contact Us
Menu
Home
About Us
Contributors
Publications
Aron 1 – Renal Cell Carcinoma
Aron 2 – Urothelial carcinoma
Aron 3 – Prostate Cancer
Aron – supplementaries
Contact Us
Publications
All our publications
Prognostic immunotherapy score (PIS) in patients with advanced urothelial carcinoma treated with pembrolizumab: real-world data and validation from ARON-2 dataset
Rizzo A, et al
Clin Exp Metastasis
2025
Real-world evidences on adjuvant Pembrolizumab for renal cell carcinoma: results from the multicenter real-world ARON-1 study
Kopp RM,
et al. Cancer Immunol Immunother
2025
Sarcomatoid Differentiation in Renal Cell Carcinoma: Clinical and Pathologic Heterogeneity and Outcomes With Immune Checkpoint Inhibitors-Data From the ARON-1 Study
Massari F, et al. JCO Glob Oncol
JCO Glob Oncol.
2025
Toxicity-related immunotherapy discontinuation and outcome in patients with advanced renal cell carcinoma treated with immune-based combinations (ARON-1 study)
Molina-Cerrillo J
et al. Int J Cancer
2025
mRNA expression, tumor heterogeneity, and response to therapy inpatients with advanced renal cell carcinoma treated with immune-basedcombinations (ARON-1α)
Aguzzi C
et al. Biochem Biophys Rep.
2025
Nivolumab plus cabozantinib in metastatic renal cell carcinoma: real-world evidence from the international ARON-1 study
Bourlon MT
et al. Front Oncol
2025
Previous
Page
1
Page
2
Page
3
Page
4
Page
5
Next